ASH 2023 – Regeneron defends its bispecifics
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
ASH 2023 – Arcellx still hopes to challenge Carvykti
The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.
ASH 2023 – J&J makes menin a three-horse race
But JNJ-75276617 still has much to prove.
Lilly makes steady progress in non-covalent BTK inhibition
Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.
ESMO Asia 2023 – deaths raise doubts about Merus’s Rybrevant challenger
Merus still hopes for a future for MCLA-129, but the doors are closing.
